 SAN DIEGO, July 20, 2021 GLOBE NEWSWIRE -- Erasca, Inc. Nasdaq: ERAS, a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RASMAPK pathway-driven cancers, today announced the closing of its initial public offering of 21,562,500 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 2,812,500 additional shares, at an initial public offering price of 16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Erasca, were 345.0 million. Erascas common stock is listed on the Nasdaq Global Select Market under the ticker symbol ERAS. 